Close Menu

NEW YORK – Bruker reported after the close of the market Monday that revenues in the third quarter fell 2 percent year over year.

For the three months ended Sept. 30, revenues decreased to $511.4 million from $521.1million in Q3 2019, beating the consensus Wall Street estimate of $483.7 million.

The company saw a 2 percent positive effect on revenues from currency translation and a positive effect of less than 1 percent from acquisitions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.